Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma

N/ACompletedNCT01960634

Grupo Español Multidisciplinar de Melanoma58 enrolled

Overview

This is a multi-centric translational study with biological samples collection. The aim of this study is to validate a method to detect BRAFV600 in blood samples. Samples: Blood from patients with BRAFV600 metastatic melanoma collected following standard medical practice. The treatment is not the aim of the study. Patients can be treated either with specific or no-specific drug.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Stage IV Skin Melanoma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed diagnosis of melanoma and BRAFV600 * Signed Informed Consent Form * Unresectable phase III or phase IV melanoma * The patients should be starting a treatment for melanoma (either first line or subsequent lines)

Locations (13)

Hospital Infanta Cristina

Madrid, Badajoz, Spain

Hospital Germans Trias i Pujol

Badalona, Barcelona, Spain

Hospital del Mar

Barcelona, Barcelona, Spain

Outcomes

Primary Outcomes

Rate of patient in which BRAF V600 in blood samples is present/absent

Time frame: two years

Secondary Outcomes

Rate of patients with BRAFV600 present in tumor sample vs blood sample

Time frame: two years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.